Slingshot members are tracking this event:

SAGE Plans to Initiate Phase 2 Trials for SAGE 217 (Essential Tremors and Orphan Epilepsies) 2nd Half of 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Update on 11.3.16:
  • Mood Disorders:
    • PPD: Sage plans to initiate a Phase 2 clinical program for SAGE-217 in PPD based on positive results to date from the SAGE-547 PPD clinical program. The Phase 2a multi-center, double-blind, placebo-controlled, randomized trial will evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in the treatment of patients with PPD.
    • MDD: Sage plans to initiate a two-part Phase 2 clinical trial of SAGE-217 in MDD. Part A of the Phase 2 trial will be an open-label, proof-of-concept study which, if positive, may lead to a larger randomized, placebo-controlled Phase 2 trial.
  • http://investor.sage...
    Slingshot Insights Explained
    Catalyst Date
    Occurred on:
    Dec 13, 2016
    Occurred Source:
    Related Projects Image
    • Don’t see a project related to the catalyst you care about?

    Related Keywords Sage-217, Phase 2 Initiation